[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601576":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":50,"collaborators":54,"id":57,"slug":30,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":30,"enrollmentInfo":66,"targetDuration":30,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":34,"whyStopped":30,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MyeloGen Germline Testing Group","EXPERIMENTAL","Enrolled participants will complete:\n\n* Baseline visit with questionnaires, educational video, and punch skin biopsy\n* Negative genetic test results notification via mail\n* Positive genetic results will be followed up by an appointment with a genetic counselor or physician\n* Post-results questionnaires\n* Follow up via medical records for up to 2 years from time of study consent.",[13],"Device: MyeloGen Gene Panel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","MyeloGen Gene Panel","The MyeloGen Gene Panel is investigational Germline genetic testing using skin fibroblasts.",[9],[21],"Custom hereditary cancer gene panel",[23],{"name":24,"affiliation":5,"role":25},"Christopher R Reilly, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","407-443-6243",null,"Christopherr_reilly@dfci.harvard.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Boston","Massachusetts","02215","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-71.05977,42.35843,{"lat":44,"lon":43},[47,49],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":48},"christopherr_reilly@dfci.harvard.edu",{"name":24,"role":25,"phone":30,"phoneExt":30,"email":30},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"SPONSOR_INVESTIGATOR","Christopher Reilly","Sponsor-Investigator",[55],{"name":56,"class":6},"Broad Institute of MIT and Harvard","100601576",false,"NCT07112287","Germline Testing for Predisposition to Myeloid Malignancies","MyeloGen: Germline Testing for Predisposition to Myeloid Malignancies","MyeloGen","Inclusion Criteria:\n\n* Age of 18 years or older\n* Participants must have histologically confirmed myeloid malignancy OR bone marrow failure within the last 6 months prior to screening.\n* Ability to understand and provide a signed and completed consent document in English.\n\nExclusion Criteria:\n\n* Participants who cannot safely undergo clinically indicated skin biopsy as adjudicated by the study team.\n* Participants who have previously undergone germline genetic testing for predisposition to myeloid malignancies","ALL","18 Years",{"count":67,"type":68},200,"ESTIMATED","INTERVENTIONAL",[71],"NA","The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.",[74,75,76],"Myeloid Malignancy","Genetic Predisposition to Disease","Myeloid Hematological Malignancies",[78,75],"Myeloid Malignancies","2026-04-21",{"date":81,"type":82},"2026-04-24","ACTUAL",{"date":84,"type":82},"2025-11-10",{"date":86,"type":68},"2033-04-01",{"name":52,"class":6},1]